Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · Real-Time Price · USD
14.96
+0.84 (5.95%)
Mar 9, 2026, 4:00 PM EDT - Market closed

Anika Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
200133237332433517
Market Cap Growth
-22.45%-43.75%-28.57%-23.26%-16.34%-20.22%
Enterprise Value
164.95100.19205.67289.37375.39442.28
Last Close Price
14.969.6116.4622.6629.6035.83
PE Ratio
--13.73-27.43-98.52197.33127.96
Forward PE
59.8453.3939.19---
PEG Ratio
5.654.604.60--161.40
PS Ratio
1.741.181.982.753.803.50
PB Ratio
1.370.931.541.571.521.80
P/TBV Ratio
1.500.961.571.571.531.83
P/FCF Ratio
44.9830.60-101.80-46.04-140.69159.01
P/OCF Ratio
17.5411.9343.92-185.7998.1961.62
EV/Sales Ratio
1.460.891.722.403.302.99
EV/EBITDA Ratio
--18.8368.1019.2120.6718.90
EV/EBIT Ratio
--9.07-40.32342.86102.29169.13
EV/FCF Ratio
37.8222.97-88.23-40.11-122.00135.92
Debt / Equity Ratio
0.170.170.160.120.100.07
Debt / EBITDA Ratio
-6.14-4.557.951.721.590.82
Debt / FCF Ratio
5.555.55-10.30-3.59-9.365.91
Net Debt / Equity Ratio
-0.23-0.23-0.20-0.20-0.20-0.26
Net Debt / EBITDA Ratio
8.456.25-10.47-2.84-3.17-3.21
Net Debt / FCF Ratio
-7.63-7.6313.565.9418.69-23.09
Asset Turnover
0.570.570.510.390.330.41
Inventory Turnover
2.302.301.821.191.071.58
Quick Ratio
3.713.713.403.064.334.17
Current Ratio
4.724.724.885.266.075.66
Return on Equity (ROE)
-6.71%-6.71%-4.82%-1.38%0.77%1.48%
Return on Assets (ROA)
-6.03%-6.03%-6.88%-0.30%0.54%1.25%
Return on Invested Capital (ROIC)
-9.92%-9.92%-10.53%-0.44%0.81%1.89%
Return on Capital Employed (ROCE)
-6.35%-6.35%-2.43%0.30%1.15%0.81%
Earnings Yield
-5.55%-7.28%-3.65%-1.02%0.51%0.78%
FCF Yield
2.22%3.27%-0.98%-2.17%-0.71%0.63%
Buyback Yield / Dilution
7.90%7.90%5.36%1.90%0.06%-0.12%
Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q